Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert

Nordstrom, 2005, Persistence and adherence with topical glaucoma therapy, Am J Ophthalmol, 140, 598, 10.1016/j.ajo.2005.04.051 Osterberg, 2005, Adherence to medication, N Engl J Med, 353, 487, 10.1056/NEJMra050100 Schwartz, 2008, Adherence and persistence with glaucoma therapy, Surv Ophthalmol, 53, S57, 10.1016/j.survophthal.2008.08.002 Newman-Casey, 2015, The most common barriers to glaucoma medication adherence, Ophthalmology, 122, 1308, 10.1016/j.ophtha.2015.03.026 Sleath, 2011, The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity, Ophthalmology, 118, 2398, 10.1016/j.ophtha.2011.05.013 Brandt, 2001, Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP, Ophthalmology, 108, 1023, 10.1016/S0161-6420(01)00584-X Kass, 2002, The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma, Arch Ophthalmol, 120, 701, 10.1001/archopht.120.6.701 Sherwood, 2001, Six-month comparison of bimatoprost once-daily and twice-daily with timolol-twice daily in patients with elevated intraocular pressure, Surv Ophthalmol, 45, S361, 10.1016/S0039-6257(01)00219-3 Allergan, Inc. Lumigan (bimatoprost ophthalmic solution) 0.01%. Full prescribing information. Available at: http://www.allergan.com/assets/pdf/lumigan_pi.pdf. Accessed December 7, 2015. Alcon, Inc. Travatan-Z (travoprost ophthalmic solution) 0.004%. Full prescribing information. Available at: http://www.myglaucomasupport.com/travatan-z-solution.shtml?utm_source=travatanz.com&utm_medium=Redirect&utm_campaign=travatanz.com. Accessed December 7, 2015. Pfizer, Inc. Xalatan (latanoprost ophthalmic solution) 0.005%. Full prescribing information. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=613. Accessed December 7, 2015. Linden, 1998, Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity?, Curr Eye Res, 17, 567, 10.1080/02713689808951229 Ocular Therapeutix, Inc. Ocular Innovation Summit, November 16, 2014, Chicago, IL. Available at: http://ois.net//wp-content/uploads/2014/10/Ocular-Therapeutix.pdf. Accessed December 7, 2015. MATI Therapeutics, Inc. Ocular Innovation Summit, November 16, 2014, Chicago, IL. Available at: http://ois.net//wp-content/uploads/2014/10/Mati-Therapeutics.pdf. Accessed December 7, 2015. Bensinger, 1976, Pilocarpine ocular inserts, Invest Ophthalmol, 15, 1008 United States Food and Drug Administration. Ocusert Pilo-20 (pilocarpine) 5 mg. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed July 17, 2015.